RxDoctor Payments DataLook up a doctor →

Sramila Aithal, MD

Medical Oncology · Bensalem, PANPI 1205029816

Payments from drug & device makers

$1,855,048in general payments, 2019–2025

Across 815 payments — averaging $2276.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$686K
  • Pfizer$216K
  • Seagen Inc.$209K
  • Gilead$157K
  • Macrogenics, Inc.$127K
  • Merck$87K
  • plus $373K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis69$685,506
Pfizer(2 entities)124$216,421
Seagen Inc.82$208,650
Gilead(2 entities)111$156,909
Macrogenics, Inc.3$127,150
Merck72$87,486
Genentech, Inc.3$84,878
Lilly USA, LLC57$67,597
Boehringer Ingelheim6$63,358
Daiichi Sankyo Inc.75$63,075
AstraZeneca(2 entities)30$47,193
Sanofi US Services Inc.2$15,645
Puma Biotechnology, Inc.20$14,947
Eli Lilly4$5,689
Sanofi8$2,962
Fresenius Kabi USA, LLC6$2,570
Boehringer Ingelheim International GmbH5$1,055
AbbVie16$469
E.r. Squibb & Sons, L.L.C.10$431
Johnson & Johnson11$302
Ipsen Biopharmaceuticals, Inc5$280
Astellas Pharma US Inc5$234
Stemline Therapeutics Inc.5$213
Eagle Pharmaceuticals, Inc.2$204
Amgen9$189
Genentech USA, Inc.5$126
Eisai Inc.5$115
Bristol Myers Squibb5$107
Bayer4$99
Acrotech Biopharma Inc.5$95
Takeda Pharmaceuticals U.S.A., Inc.4$92
Coherus Oncology, Inc.2$87
G1 Therapeutics, Inc.4$80
ADC Therapeutics America, Inc.3$54
Alnylam Pharmaceuticals Inc.2$50
Aadi Bioscience, Inc.2$44
Genmab U.S., Inc.2$44
Beigene USA, Inc.2$43
Exelixis Inc.2$42
Kyowa Kirin, Inc.2$42
Servier Pharmaceuticals LLC2$35
AVEO Pharmaceuticals, Inc.2$33
Beone Medicines USA, Inc.1$33
Karyopharm Therapeutics Inc.1$30
Sobi, Inc1$27
Incyte Corporation1$24
Regeneron Healthcare Solutions, Inc.1$23
Mirati Therapeutics, Inc.1$23
Morphosys, US Inc.1$22
Springworks Therapeutics, Inc.1$22
Adaptive Biotechnologies Corporation1$22
Myriad Genetic Laboratories, Inc.1$21
GSK1$21
Array Biopharma Inc1$20
Pharmacosmos Therapeutics Inc.1$19
Organon1$18
Heron Therapeutics, Inc.1$18
Pharmacyclics LLC, An Abbvie Company1$18
Blueprint Medicines Corporation1$17
EMD Serono, Inc.1$15

How this compares

$1,855,048 in reported general payments places this provider in the 80th percentile of 238 medical oncology providers in Pennsylvania.

See all medical oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$1,988,144
Medicare patients
375
Services billed
94,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Bensalem

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →